Octopus Ventures is a venture capital firm that offers support to companies at various stages of their journey, from idea conception to IPO. They allocate over £200 million annually to invest in sectors such as health, fintech, deep tech, consumer, and B2B software, with a focus on making a positive impact. Their experienced team assists portfolio companies in scaling rapidly. Octopus Ventures' investment philosophy extends beyond monetary support, involving time, energy, and focus to work closely with founders for success. Notable companies they have backed include ManyPets, Cazoo, Depop, Elvie, and WaveOptics. Their operations span London and New York, with a network of partners in the U.S. and Asia.

Octopus Ventures

Felicis Ventures is a venture capital firm based in Menlo Park, California. The firm invests in seed through Series C stage companies across multiple sectors and industries reinventing core markets, as well as those creating frontier technologies. Felicis currently manages over $2B in capital across 8 funds. The firm is an early backer of more than 40 companies valued at $1B+. More than 90 of its portfolio companies have been acquired or gone public since the firm was founded by Aydin Senkut in 2006.

Felicis

Google Ventures invests in sectors including life sciences, consumer, enterprise, crypto, climate, and frontier technology. With Alphabet as its sole limited partner, Google Ventures focuses on long-term investments. Its operating partners assist startups in design, equity, diversity & inclusion, talent, and engineering and help them connect with Google for technology and expertise. Founded in 2009 as Google Ventures, Google Ventures manages over $8 billion in assets with 400 active portfolio companies in North America and Europe. Some notable investments include Uber, Nest, Slack, GitLab, and One Medical. Google Ventures is based in the San Francisco Bay Area with offices in Cambridge, New York, and London.

Google Ventures

Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technology.

Khosla Ventures

What If Ventures invests in stigmatized verticals within the healthcare market. For too long, stigma has artificially suppressed demand for care in indications such as mental health, fertility, and many others.  Societal changes are creating markets where stigma once stood in the way of people getting the care they need. The firm was founded in 2019 by Stephen Hays, after his own personal struggles with mental health and addiction fueled his desire to see more funding for solutions in that space.  Since then, the firm has broadened its aperture and has deployed nearly $80mm into more than 60 disruptive healthcare startups.

What If Ventures

Evolution-VC is involved in investments and strategic partnerships to create a global platform that unites leaders, investors & corporates.

Evolution Ventures

Wisdom Ventures is seed venture fund in San Francisco, investing globally in compassion and wellness start-ups;  leveraging a partner team with extensive networks and proven track record as investors, experts and leaders.

Wisdom Ventures

Overture Life

Overture Life is a biotechnology company committed to making vitro fertilization more accessible to everyone. Overture Life creates medical devices and novel embryo testing methodologies that automate the entire IVF process, increasing throughput for IVF practitioners. Overture Life makes artificial insemination more accessible by lowering costs, optimizing resource use, and increasing success rates.

Overture Life provides “Naturalife” embryology mini-lab technology that automates manual processes in embryology and in vitro fertilization (IVF) to reduce the disparity in success rates between fertility clinics, while also reducing the cost of artificial insemination. NaturaLife was launched in November 2019 and can perform non-invasive genetic embryo testing, egg freezing, and embryo vitrification.

Long-term demographic changes are finally bringing fertility technologies into focus.

Fertility Tech

Hans Gangeskar and Overture Life: Revolutionizing IVF with ...

Overture Life provides “Naturalife” embryology mini-lab technology that automates manual processes in embryology and in vitro fertilization (IVF) to reduce the disparity in success rates between fertility clinics, while also reducing the cost of artificial insemination. NaturaLife was launched in November 2019 and can perform non-invasive genetic embryo testing, egg freezing, and embryo vitrification.&nbsp;As of May 2021, the company employed around 60 specialists across the fields of software, microfluidics, robotics, embryology, and reproductive medicine, and was developing its products in its Barcelona and Madrid facilities.&nbsp;&nbsp;Key customers and partnerships&nbsp;In 2023, Overture Life collaborated with New Hope Fertility Center in New York City to use its robotic technology for sperm injection during IVF procedures. This partnership led to the birth of two healthy babies conceived through the automated process.

Glow offers apps that track data related to women’s fertility including ovulation cycle and pregnancy tracking. In addition to apps, the company also offers individualized fertility coaching, clinic identification and community support, and links patients with clinics for procedures such as egg freezing.&nbsp;In 2020, the company faced investigations into privacy and security failures involving its app. Glow agreed to pay a USD 0.25 million settlement in September 2020.&nbsp;Key customers and partnershipsAs of&nbsp;November 2024, it had 25 million+ users and claims to have helped about 1.7 million women get pregnant. Glow's user base includes women from various industries seeking to monitor their reproductive health. The company has established partnerships with healthcare providers to enhance its offerings.In March 2024, Glow partnered with Natalist to offer its users exclusive access to Natalist’s products and resources including prenatal vitamins and supplements, educational resources on a variety of reproductive health topics, and support from a team of registered nurses and lactation consultants.In February 2024, the company partnered with Mira to provide its users with education on hormone health, hormone tracking, and exclusive discounts on Mira Hormone Monitor: Max Kit and Fertility Max Wands.&nbsp;

Glow

Inne, based in Germany, offers an at-home mini lab kit for women. Hormone analysis is conducted based on saliva samples. The lab device connects to smartphones for storage and access to the analysis results.Unlike peer offerings, Inne does not attempt to predict future cycles and fertility dates, and instead educates users about their bodies, with information on what changes they should feel in response to the hormonal levels on the day.&nbsp;Key customers and partnershipsIn<a href="https://www.femtechworld.co.uk/news/start-up-inne-raises-us10m-to-expand-hormone-tracking-platform/?utm_source=chatgpt.com"> May 2022</a>, Inne announced a strategic partnership with Phenology. The collaboration aimed to introduce Inne's hormone-tracking technology to the US market, focusing on assisting women in tracking hormonal changes during perimenopause.&nbsp;

Inne

Proov (formerly known as MFB Fertility) offers the at-home “Proov'' ovulation and progesterone test. Proov tracks hormone levels in urine over multiple days, after suspected ovulation, and estimates whether the progesterone levels are sufficient for implantation, during the 7-10 day implantation window.Proov was the first FDA-cleared urine PdG (urine metabolite of the progesterone hormone) test and its method of determining the fertile window was patented&nbsp;in 2021. Moreover, it received the CE marking and expanded its sales footprint to Europe in June 2021.&nbsp;Key customers and partnershipsIn June 2024, Proov partnered with Wisp to integrate Proov's at-home fertility tests into Wisp's services. This collaboration aimed to offer comprehensive fertility care, including ovulation medications and testing, to individuals seeking to conceive.In July 2023, Proov collaborated with Quest Diagnostics to make the Proov Confirm PdG home collection kit available through questhealth.com. This test is claimed to be the first FDA-cleared PdG (progesterone metabolite) home test kit designed to confirm successful ovulation. The partnership aimed to broaden access to Proov's testing solutions.&nbsp;&nbsp;

Proov

Progyny works with employers (primarily large enterprises in the US) to optimize the fertility benefits they offer for their employees. It connects employees to fertility specialists and clinics, and also offers extensive support to patients through their Progyny Patient Care Advocates, who provide clinical guidance, education, and emotional support.The company was founded as a fertility education platform and eventually included in vitro fertilization (IVF) referral network Fertility Authority and reproductive health company Auxogyn, into its network. The company pivoted into offering fertility benefit solutions in 2016, and launched Progyny Rx (fertility medication benefit) in 2018.Progyny connects patients to a network of 800 fertility specialists and nearly 600 clinic locations.&nbsp;Progyny’s revenue exceeded USD 1 billion for the first time in FY 2023 and cash flow from operations were recorded as USD 188.8 million for the period. Adjusted EBITDA for the period was USD 187.1 million, a 49% increase YoY from the USD 125.7 million reported in FY 2022.Key customers and partnershipsAs of March 2022, the company served 264 enterprise customers (including Facebook, Microsoft, Google, and Nasdaq), and had 3.9 million active members.In March 2023, Progyny was selected as the exclusive partner for fertility and family building benefits by CHA, representing over 220 children's hospitals with more than 2 million covered lives. This partnership enabled CHA member hospitals to offer comprehensive fertility solutions to their employees.

Progyny

Prima Temp offers the artificial intelligence (AI) assisted “Priya” intravaginal ring sensor and accompanying app to continuously measure a woman’s core body temperature, predicting fertility windows. The app uses big data to improve its predictions, and the app notifies the user of fertile windows. The company also offers the “Kindara” fertility tracking app, which provides fertility-related education and links users to a community of over 140,000 members.&nbsp;&nbsp;&nbsp;Key customers and partnerships&nbsp;In&nbsp;<a href="https://www.prnewswire.com/news-releases/enfamil-and-prima-temp-enter-collaboration-to-support-women-on-fertility-journey-301111251.html?utm_source=chatgpt.com">August 2020</a>, Prima-Temp entered a co-marketing agreement with infant formula brand Enfamil to offer educational resources and discounts on products and services, including Enfamom prenatal vitamins and Prima-Temp's fertility tracking solutions.&nbsp;In&nbsp;<a href="https://www.prnewswire.com/news-releases/prima-temp-announces-new-team-and-new-international-initiative-300604615.html?utm_source=chatgpt.com">February 2018</a>, the company entered into an exclusive licensing and distribution agreement with Hungarian pharmaceutical company Gedeon Richter to commercialize its Priya fertility sensor globally (excluding the US and Canada). The collaboration aimed to leverage Gedeon Richter's global network to bring the Priya sensor to international markets.

Prima Temp

Test kits which use saliva, blood, or temperature to determine hormone levels and form conclusions on fertility and fertility cycles.


Apps which use data science to identify fertility windows.

Organizations that freeze eggs or embryos for usage at a future date.


Services that analyze sperm samples (via test kit) and/or offer storage facilities for future use.

Companies specializing in supporting patient decision making, financing, clinical visits, physician referrals, and at-home treatments

Offers digital platforms and apps to provide fertility-related support

Uses AI/ML to improve cycle predictions and track symptoms

Some startups use genetic screening to tailor treatment or identify underlying issues

Overture Life

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless